Anti-SARS-CoV-2 Antibody Testing: Role and Indications
Since the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortal...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/24/7575 |
| _version_ | 1797380563898728448 |
|---|---|
| author | Sylvia Mink Peter Fraunberger |
| author_facet | Sylvia Mink Peter Fraunberger |
| author_sort | Sylvia Mink |
| collection | DOAJ |
| description | Since the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortality rates continue to be registered. Both recent spikes in case numbers and the continued emergence of new variants suggest that vulnerable patient groups, including older adults, immunocompromised patients, and patients with severe comorbidities, are going to continue to be affected by COVID-19. In order to curb the pandemic, relieve the pressure on primary care facilities, and reduce mortality rates, global vaccination programs have been established by the WHO, with over 13.5 billion vaccine doses having been administered globally. In most immunocompetent individuals, vaccination against COVID-19 results in the production of anti-SARS-CoV-2 spike antibodies. However, certain patient subsets have inadequate or reduced immune responses, and immune responses are known to decrease with age. General recommendations on the timing of booster vaccinations may therefore be insufficient to protect vulnerable patients. This review aims to evaluate the clinical role of anti-SARS-CoV-2 antibodies, focusing on measurement indications, prognostic value, and potential as a correlate of protection to guide future booster vaccination strategies. |
| first_indexed | 2024-03-08T20:39:07Z |
| format | Article |
| id | doaj.art-af4322cb08fd401d8222091ef6ef3ec5 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T20:39:07Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-af4322cb08fd401d8222091ef6ef3ec52023-12-22T14:17:02ZengMDPI AGJournal of Clinical Medicine2077-03832023-12-011224757510.3390/jcm12247575Anti-SARS-CoV-2 Antibody Testing: Role and IndicationsSylvia Mink0Peter Fraunberger1Central Medical Laboratories, 6800 Feldkirch, AustriaCentral Medical Laboratories, 6800 Feldkirch, AustriaSince the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortality rates continue to be registered. Both recent spikes in case numbers and the continued emergence of new variants suggest that vulnerable patient groups, including older adults, immunocompromised patients, and patients with severe comorbidities, are going to continue to be affected by COVID-19. In order to curb the pandemic, relieve the pressure on primary care facilities, and reduce mortality rates, global vaccination programs have been established by the WHO, with over 13.5 billion vaccine doses having been administered globally. In most immunocompetent individuals, vaccination against COVID-19 results in the production of anti-SARS-CoV-2 spike antibodies. However, certain patient subsets have inadequate or reduced immune responses, and immune responses are known to decrease with age. General recommendations on the timing of booster vaccinations may therefore be insufficient to protect vulnerable patients. This review aims to evaluate the clinical role of anti-SARS-CoV-2 antibodies, focusing on measurement indications, prognostic value, and potential as a correlate of protection to guide future booster vaccination strategies.https://www.mdpi.com/2077-0383/12/24/7575COVID-19booster vaccinationanti-SARS-CoV-2 antibodiesSARS-CoV-2antibody testingcorrelate of protection |
| spellingShingle | Sylvia Mink Peter Fraunberger Anti-SARS-CoV-2 Antibody Testing: Role and Indications Journal of Clinical Medicine COVID-19 booster vaccination anti-SARS-CoV-2 antibodies SARS-CoV-2 antibody testing correlate of protection |
| title | Anti-SARS-CoV-2 Antibody Testing: Role and Indications |
| title_full | Anti-SARS-CoV-2 Antibody Testing: Role and Indications |
| title_fullStr | Anti-SARS-CoV-2 Antibody Testing: Role and Indications |
| title_full_unstemmed | Anti-SARS-CoV-2 Antibody Testing: Role and Indications |
| title_short | Anti-SARS-CoV-2 Antibody Testing: Role and Indications |
| title_sort | anti sars cov 2 antibody testing role and indications |
| topic | COVID-19 booster vaccination anti-SARS-CoV-2 antibodies SARS-CoV-2 antibody testing correlate of protection |
| url | https://www.mdpi.com/2077-0383/12/24/7575 |
| work_keys_str_mv | AT sylviamink antisarscov2antibodytestingroleandindications AT peterfraunberger antisarscov2antibodytestingroleandindications |